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Abstract This review on platelet research focuses on
defects of adhesion, cytoskeletal organisation, signal trans-
duction and secretion. Platelet defects can be studied by
different laboratory platelet functional assays and morphol-
ogical studies. Easy bruising or a suspected platelet-based
bleeding disorder is of course the most obvious reason to
test the platelet function in a patient. However, nowadays
platelet research also contributes to our understanding of
human pathology in other disciplines such as neurology,
nephrology, endocrinology and metabolic diseases. Apart
from a discussion on classical thrombopathies, this review
will also deal with the less commonly known relation
between platelet research and disorders with a broader
clinical phenotype. Classical thrombopathies involve dis-
orders of platelet adhesion such as Glanzmann thrombas-
tenia and Bernard-Soulier syndrome, defective G protein
signalling diseases with impaired phospholipase C activa-
tion, and abnormal platelet granule secretion disorders such
as gray platelet disorder and delta-storage pool disease.
Other clinical symptoms besides a bleeding tendency have
been described in MYH9-related disorders and Duchenne
muscular dystrophy due to adhesion defects, and also in
disorders of impaired Gs signalling, in Hermansky Pudlack
disease and Chediak Higashi disease with abnormal
secretion. Finally, platelet research can also be used to
unravel novel mechanisms involved in many neurological
disorders such as depression and autism with only a
subclinical platelet defect.
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Abbreviations
ADP Adenosine diphosphate
BSS Bernard-Soulier syndrome
GABA Gamma-aminobutyric acid
GP Glycoprotein
MYH9 Myosin heavy chain 9
PACAP Pituitary adenylyl cyclase-activating polypeptide
PFA100 Platelet function analyzer 100
PLC Phospholipase C
SNARE Soluble NSF attachment receptor
SPD Storage pool disease
TXA2 Thromboxane A2
VIP Vasointestinal peptide
vWF Von Willebrand factor
Introduction
Normal hemostasis prevents spontaneous bleeding and
traumatic hemorrhage by a coordinated sequence of cellular
andbiochemicalreactionstothe ultimateformationofa stable
platelet-fibrinaggregate [20]. Platelets, under normal circum-
stances, circulate in close contact to the endothelial cell
lining of the vessel wall, and respond to vascular damage by
adhering to subendothelial structures. Platelet adhesion is the
first step in the hemostatic plug formation [11]. The major
platelet receptors involved in this process are the von
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the collagen integrin receptor α2β1, and the fibrinogen
integrin receptor αIIBβ3 (Fig. 1a). Subsequent platelet
spreading is conducted by cytoskeleton proteins including
the structural subunit of the microtubules, the αβ-tubulin
heterodimer, filamin and actin (Fig. 1a). The cytoskeleton is
responsible for the shape of the resting platelet and carries
out contractile events such as the secretion of granules and
retraction of clots by activated cells.
Platelet adhesion also initiates multiple intracellular G
protein-coupled signalling pathways (Fig. 1b). Stimulation
of Gq by different ligands such as adenosine diphosphate
(ADP) and thromboxane A2 (TXA2) results in platelet
activation by stimulating phospholipase C and a release of
calcium from the intracellular stores. This platelet activation
process is enhanced when Gi is activated and inhibited
when Gs is activated both by modulating the intracellular
cAMP level.
Platelet adhesion and activation eventually results in
secretion from platelet organelles (Fig. 1c) [37]. Resting
platelets circulate as discoid anuclear cells and consist of a
lipid bilayer and an internal dense tubular system, where
calcium is sequestered. The platelet cytoplasm contains
mitochondria, glycogen particles, lysosomes, and the
platelet-specific storage granules: the α-granules and dense
granules (Fig. 2). The α-granules contain proteins such as
platelet factor 4, β-thromboglobulin, platelet derived
growth factor, fibrinogen, fibronectin, thrombospondin,
plasminogen activator inhibitor I and vWF. Dense bodies
are rich in serotonin, ATP, ADP and calcium.
The study of platelet adhesion, G protein signalling and
secretion is particularly useful for our understanding of
several clinical disorders (Table 1). The most obvious
reason is of course the study of platelet defects in patients
with an isolated platelet disorder leading to bleeding or
thrombosis in order to gain additional information on the
different pathways involved in platelet function. The
analysis of human disorders in which the defective platelet
phenotype is just one part of its clinical spectrum to unravel
novel biological and genetic mechanisms involved in the
disease. Also, using platelet functional and morphological
studies can be used as a tool to find novel pathways
involved in more complex disorders usually caused by
more than one gene defect. Recently, it became obvious
that the molecular pathways involved in more complex
human disorders such as diabetes type 2 or neurological
disorders such as schizophrenia, migraine, bipolar disorder,
and depression can also be better understood by studying
platelet signalling and secretion. Due to space limitations, it
is impossible to give a full overview of all human disorders
studied today by means of platelet research. This review
describes some well-known as well as some less common
disorders to illustrate how platelet research contributes to
the understanding of thrombopathies [13, 35] as well as the
broader future of this research outside its classical field of
thrombosis and hemostasis (Table 1).
When considering type of platelet tests
A clinical platelet-based bleeding problem is of course the
main reason to investigate platelet function and morphol-
ogy. The diagnostic approach to easy bruising or a sus-
pected platelet-based bleeding disorder includes a careful
history and physical examination of the patient as well as
different laboratory investigations such as the Ivy bleeding
time, platelet aggregation tests, ATP secretion, platelet
adhesion by the platelet function analyzer (PFA100) and
platelet morphology by electron microscopy [13, 40].
Reviewing the medical history can already establish
whether the disorder is hereditary or acquired. The specific
clinical findings useful in the differential diagnosis of
coagulation versus platelet-based disorders are summarized
in Table 2. Frequently, mucocutaneous bleedings charac-
terize abnormalities of platelet function. In contrast,
hemorrhage into synovial joints and deep muscular hemor-
rhage are signs of severe hereditary coagulation disorders
and very rare events in disorders of platelets, vessels or
acquired coagulation disorders. Inherited disorders of
platelet function are further subdivided based on the
functions or responses that are abnormal and therefore can
belong to different subgroups including abnormal platelet
adhesion, signalling and secretion [36]. Platelet-based
bleeding disorders are usually classified according to
abnormalities of platelet function, platelet number (throm-
bocytopenia) or both [36].
Functional and morphological platelet studies in
patients with mainly a neurological, metabolic or another
clinical problem but no obvious bleeding problem are
usually not performed for diagnostic purposes but rather
for research aims. In such patients, novel insights are
Fig. 1 a Schematic model of the main components involved in
platelet adhesion and the cytoskeleton proteins. Platelet adhesion and
its subsequent activation by calcium release is mainly regulated by the
platelet receptor αIIbβ3 after binding to fibrinogen or the RGD
domain of vWF, the main vWF receptor GPIb/IX/V and the collagen
receptor α2β1. Microtubules together with the cytoplasmic, actin-rich
cytoskeleton are responsible for the platelet structure. Different actin
binding proteins have been identified in platelets such as filamin A,
myosin and dystrophin. b Schematic model of G protein signal
transduction in platelets regulated by Gq for platelet activation by the
ultimate step of calcium release. Gi and Gs further influence the platelet
activation by respectively inhibiting and stimulating the intracellular
cAMP formation. c Schematic model of platelet secretion. The second
amplification step in platelet activation is the release of alpha and
dense granules in platelets guarantying irreversible platelet activation

1204 Eur J Pediatr (2007) 166:1203–1210expected to result from the platelet research studies, which
are still preliminary today but in the future hopefully will
help to better define when to ask for what type of platelet
tests in a given patient.
Thrombopathies
Glanzmann thrombasthenia and the Bernard-Soulier syn-
drome (BSS) are two rare inherited disorders of platelet
Eur J Pediatr (2007) 166:1203–1210 1205adhesion. Glanzmann thrombasthenia (MIM 273800) is an
autosomal recessive disorder, characterized by prolonged
bleeding time and abnormal clot retraction [30, 31, 35]. The
hallmark of this disease is severely reduced or absent
platelet aggregation in response to various physiological
platelet agonists such as ADP, thrombin and collagen. The
defect is caused by mutations in one of the integrin genes,
ITGA2 or ITGB3, encoding the αIIbβ3 receptor complex.
Lack of expression or qualitative defects in αIIbβ3 results
in a disturbed interaction between activated platelets and
adhesive glycoproteins (fibrinogen at low shear and vWF at
high shear) that bridge adjacent platelets during platelet
aggregation (Fig. 1a). The Bernard-Soulier syndrome (MIM
231200) is caused by abnormalities in the GP Ib/IX/V
receptor complex due to mutations in the genes for GPIbα,
GPIbβ or GPIX (but there are no reports of BSS affecting
the GPV gene) [22]. It is an autosomal recessive disorder with
moderate to severe macrothrombocytopenia, decreased plate-
let survival and often a spontaneous bleeding tendency. The
bleeding events can be severe but are usually controlled by
platelet transfusion. Most heterozygotes, with a few excep-
tions, do not have a bleeding diathesis. BBS platelets ag-
gregate normally in response to physiological agonists (ADP
and collagen), have a weak response towards low con-
centrations of thrombin and do not agglutinate when platelet
rich plasma is stirred with ristocetin or botrocetin [22].
Defects in G protein signaling resulting in an isolated
platelet defect [36] are expected to be caused by a mutant G
protein-coupled receptor (GPCR) since these can be cell-
specific while the G proteins and their downstream effectors
in this pathway are ubiquitously expressed. A dominantly
inherited mutation (Arg60Leu) in the Gq-coupled TXA2
receptor was described in patients with a mild bleeding
disorder characterized by defective platelet aggregation
responses to TXA2 and its analogues (MIM 188070) [15].
In cultured cells, the Arg60Leu mutant was shown to impair
phospholipase C (PLC) activation. Patients can be heterozy-
gous (with some PLC activation left) or homozygous
(without PLC activation) for this mutation but all have a
life-long history of mucosal bleeding and easy bruising but
no episodes of major bleeding such as hematuria, gastroin-
testinal bleeding or hemarthrosis [14]. The Gi-coupled ADP
receptor P2Y12 (Fig. 1b) is responsible for the sustained, full
aggregation response to ADP. P2Y12 deficiency (MIM
609821) is an autosomal recessive bleeding disorder charac-
terized by excessive bleeding, prolonged bleeding time and
abnormalities that are very similar to those observed in
patients with secretion defects (reversible aggregation in
response to weak agonists and impaired aggregation towards
low concentrations of collagen and thrombin), except for the
severely impaired response to ADP [2]. Study of the
heterozygous P2Y12 defect revealed platelets that undergo
a normal first wave of ADP induced aggregation but
abnormal ATP secretion with different agonists [3, 42].
A defective platelet secretion is described for patients
with absent alpha granules (gray platelet syndrome) or ab-
normal dense granules (delta-storage pool disease, δ-SPD)
[37]. Gray platelet syndrome or α-SPD (MIM 139090)
owes its name to the fact that the typically enlarged plate-
lets devoid of α-granule staining, present with a gray color
in a Wright-stained blood smear [32]. Most cases are
sporadic though some family studies suggest an autosomal
dominant inheritance. Affected members have a life-long
history of mucocutaneous bleeding, which may vary from
mild to moderate in severity, prolonged bleeding time, mild
thrombocytopenia, abnormally large platelets and an isolat-
ed reduction of the platelet α-granule content. The
molecular defect(s) in α-SPD have not yet been defined
and further insights into the molecular mechanisms respon-
sible for platelet exocytosis (as the SNARE proteins) will
help in the search for causes of human platelets secretory
disorders. δ-SPD (MIM 185050) may present as an isolated
platelet function defect or can be associated with a variety
of other congenital defects (see further). δ-SPD is charac-
terized by a bleeding diathesis of variable degree, mildly to
moderately prolonged skin bleeding time (fully related to
the amount of ADP or serotonin contained in the granule),
abnormal platelet secretion induced by several agonists and
a reduced platelet aggregation. The δ-SPD platelets have
decreased levels of the dense granule contents: ATP and
ADP, serotonin, calcium and pyrophosphate (Fig. 1c). It
was estimated that 10–18% of patients with a congenital
abnormality of the platelet function have δ-SPD [12]. The
Fig. 2 Electron microscopy (original magnification ×22,500) of
platelets showing the dense tubular system (DTS), microtubules
(MT), open canalicular system (OCS), alpha granules (G), glycogen
(Gly) and the dense bodies (DB)
1206 Eur J Pediatr (2007) 166:1203–1210inheritance pattern is autosomal recessive in some families
while autosomal dominant in others but the molecular
players responsible for δ-SPD are still unknown.
Human disorders comprising a platelet defect
Defects in platelet adhesion and subsequent platelet
activation can also be due to an alteration in the platelet
cytoskeletal organization, which consists of the micro-
tubules and F-actin coupled to myosin, filamin and
dystrophin [29]. Mutations in these widely expressed
proteins result in a broader clinical phenotype. May-
Hegglin anomaly (MIM 155100), Fechtner syndrome
(MIM 153640), Epstein syndrome (MIM 153650), and
Sebastian syndrome (MIM 605249) are characterized by
Table 1 Syndromic and non-syndromic platelet defects and the implicated genes according to the defective platelet pathway
Type of platelet defect Isolated platelet disorders Disorders including a platelet defect Disorders studied by functional
platelet assays
Adhesion and
cytoskeletal
defects
Glanzmann thrombastenia May-Hegglin anomaly, Fechtner
syndrome, Epstein syndrome, and
Sebastian syndrome
Neurological disorders as
bipolar disorder, schizophrenia,
depression, autism
Prolonged bleeding time All: macrothrombocytopenia, prolonged
bleeding time
No other clinical problems All: leucocyte inclusions, Epstein,Fechtner:
nephritis, deafness, cataracts
ITGB3 or ITGA2 MYH9
Bernard-Soulier Syndrome Duchenne Muscular Dystrophy
Macrothrombocytopenia,
prolonged bleeding time
Prolonged bleeding after surgery
No other clinical problems Muscle degeneration
GPIbα, GPIbβ or GPIX DMD
G protein signalling defects ADP P2Y12 receptor Inducible Gsα hyperfunction syndrome Subclinical platelet defect
Prolonged bleeding time Prolonged bleeding time after trauma
No other clinical problems Brachydactyly, increased alkaline
phosphatase and neurological or
growth retardation
P2Y12 XLαs
Thromboxane TXA2 receptor PACAP overexpression
Prolonged bleeding time Prolonged bleeding time
No other clinical problems Mental retardation and hypogonadism
TXA2R PACAP
Secretion defects Gray platelet disorder Hermansky Pudlack disease Neurological defect?
Prolonged bleeding time Prolonged bleeding time
No other clinical problems Albinism, lysosomal defect
? HSP 1–8
Delta storage Pool disease Chediak Higashi disease
Prolonged bleeding time Prolonged bleeding time
No other clinical problems Albinism, immunological lethal defect
? LYST
The following implicated genes are indicated in bold: ITGB3 integrin beta3; ITGA2 integrin alpha2; GPIbα glycoprotein Ibalpha; GPIbß
glycoprotein Ibbeta; GPIX glycoprotein IX; P2Y12 purinergic receptor 12; TXASR thromboxane A2 receptor; MYH9 nonmuscle myosin heavy
chain 9; DMD Dystrophin; XLαs extra-large stimulatory G protein alpha subunit; PACAP pituitary adenylate cylase-activating peptide; HSP 1–
8 Hermansky Pudlack genes 1 through 8; LYST lysosomal trafficking regulator
Table 2 Clinical presentation of coagulation and platelet-based
bleeding disorders
Clinical
symptoms
Disorders of
coagulation
Disorders of
platelets
Petechiae,
epistaxis
Rare Characteristic
Superficial
ecchymoses
Common: large
and solitary
Characteristic:
small and multiple
Bleeding from
superficial cuts
and bruises
Minimal Persistant:
often profuse
Delayed bleeding Common Rare
Deep dissecting
hematomas
Characteristic Rare
Hemarthrosis Characteristic Rare
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leukocyte inclusions, which can only be differentiated by
an accurate ultrastructural examination [38]. In addition,
patients with Epstein or Fechtner syndrome also suffer from
nephritis, deafness, and congenital cataracts. Recently it
became obvious that Sebastian platelet syndrome, May-
Hegglin anomaly, Fechtner and Epstein syndrome have
mutations in the same gene MYH9, encoding the 224-kD
nonmuscle myosin heavy chain 9 polypeptide [26]. This
gene is expressed in platelets, monocytes, granulocytes, the
kidney, the auditory system but also in a lot of other tissues.
MYH9 deficiency results in an alteration of the composi-
tion and agonist-induced reorganization of the platelet
cytoskeleton [1, 6]. The cytoskeletal defect could also
explain the abnormal platelet formation from megakaryo-
cytes, resulting in thrombocytopenia and giant platelets in
MYH9 deficiency. Why patients with May-Hegglin anom-
aly, Fechtner syndrome, Epstein syndrome and Sebastian
platelet syndrome have different signs and symptoms in
other tissues than their common defect in platelets still
remains to be elucidated.
Duchenne muscular dystrophy (DMD) is an X-linked
recessive disease (MIM 310200) characterized by progres-
sive degeneration of muscle resulting in early death from
respiratory or cardiac failure. DMD is caused by mutations
in the dystrophin gene, a 427-kDa membrane-associated
cytoskeletal protein. Evidence for a role of dystrophin in
platelets started with the observation that DMD patients
tend to bleed more during spinal surgery for scoliosis than
do patients during the same surgery with other underlying
conditions [7]. Other C-terminal isoforms of dystrophin due
to differential promoter usage and/or alternative splicing at
the 3′-end of the gene have been identified in platelets
(Dp71), the retina (Dp260) and in the peripheral (Dp116)
and central nervous systems (Dp140). It is well established
that platelets contain a complex membrane cytoskeleton
that resembles, at least in part, the cytoskeleton found in
muscle, but a role for dystrophin during platelet activation
still remains to be clarified [18, 27]. Recent studies showed
a role for dystrophin in normal controls during platelet
spreading and adhesion by regulating the α2β1 receptor but
this was not studied in DMD patients [4, 5]. Another study
describes a normal platelet function in DMD patients and
blames the selective defect of primary hemostasis in DMD
to impaired vessel reactivity [43].
Patients with an abnormal signal transduction are a
heterogeneous group combined of defects in platelet G
protein-coupled receptors (GPCR), the G proteins, and their
effectors. Due to an extreme complex regulation between
those key components (Fig. 1b), the incidence of this class
of defects is definitely underestimated and the underlying
molecular defects for the signaling problems are still largely
unknown. Platelet Gs activity is easily determined using the
platelet aggregation-inhibition test which gives a value for
the Gs activity based on the inhibition of platelet
aggregation by the rapid generation of cAMP after
incubation with different Gs agonists such as prostacyclin
or prostaglandin (Fig. 1b). A congenital Gs hyperfunction
syndrome was described in three patients of two unrelated
families due to a paternally inherited functional polymor-
phism in the extra-large stimulatory G-protein gene (XLαs)
and its overlapping cofactor ALEX [8]. This XLαs variant
is associated with Gs hyperfunction in platelets, leading to
an increased trauma-related bleeding tendency but is also
accompanied by neurological problems and brachydactyly
(MIM 139320). A subsequent study revealed eight addi-
tional patients who paternally inherited the same XLαs
polymorphism presenting with platelet Gs hyperfunction,
brachydactyly, increased alkaline phosphatase and neuro-
logical problems or growth deficiency [9, 17].
Megakaryocytes and platelets express the Gs-coupled
VPAC1 receptor, for which both the pituitary adenylyl
cyclase-activating polypeptide (PACAP) and the vasointes-
tinal peptide (VIP) are specific agonists. Studies in two
related patients with a partial trisomy 18p revealed three
copies of the PACAP gene and elevated PACAP concen-
trations in plasma. The patients suffer from multiple neuro-
logical (epilepsy, hypotonia, convulsions, mental retardation,
tremor, psychotic, hyperactive behavior), gastro-intestinal
(diarrhea, vomiting) and endocrinological (hypoplasia of the
pituitary gland, hypogonadotropic hypogonadism) problems
and have a pronounced bleeding tendency (MIM 102980)
[10]. The basal cAMP level in the patients' platelets was
strongly elevated, providing a basis for the strongly reduced
platelet aggregation. The VPAC1 signalling pathway also
mediates megakaryocyte maturation and platelet formation
(unpublished results). Patients with PACAP overexpression
have a mild thrombocytopenia, a normal platelet survival,
relatively small platelets and their bone marrow examination
reveals almost no mature megakaryocytes.
There exist two rare syndromic forms of the δ-SPD: the
Hermansky-Pudlak syndrome (HPS) and the Chediak-
Hygashi syndrome (CHS). HPS (MIM 203300) consists
of several genetically different autosomal recessive disor-
ders, which share the clinical manifestations of oculocuta-
neous albinism, bleeding, and lysosomal ceroid storage
resulting from defects of multiple cytoplasmic organelles:
melanosomes, platelet-dense granules, and lysosomes
hypopigmentation [25, 36]. HPS can arise from mutations
in at least eight different genes known to date (HSP1 to
HSP8), all coding for proteins involved in the formation,
trafficking or fusion of intracellular vesicles of the
lysosomal lineage [44]. CHS (MIM 214500) is also an
autosomal recessive disorder, characterized by variable
degrees of oculocutaneous albinism, large peroxidase-
positive cytoplasmic granules in hematopoietic and non-
1208 Eur J Pediatr (2007) 166:1203–1210hematopoietic cells, δ-SPD, recurrent infections, neutropenia,
and an accelerated chronic lymphohistiocytic infiltration
phase. The only known CHS-causing gene, LYST, codes for
a largeproteinofunknownfunctionbut itseems thatCHS isa
disease of vesicle trafficking [16]. Most CHS patients present
in early childhood and die before the age of 7 years unless
treated by bone marrow transplantation [21]. About 10–15%
of patients exhibit a much milder clinical phenotype and
survive to adulthood but develop progressive and often fatal
neurological dysfunction.
Human disorders examined by functional
and morphological platelet assays
Some mainly polygenetic disorders can also be studied by
using platelets although the patients only present with a
subtle subclinical platelet phenotype. It is not easy to define
disorders such as diabetes type 2 or some neurological
diseases according to a defective adhesion, G protein
signalling and secretion since the platelet defect is not yet
well studied and usually overlaps different pathways. This
part of the review will only briefly focus on the use of
platelet research in our understanding of neurological
disorders. It has been known for years that certain cellular
functions are very similar in platelets and in neurosecretory
cells [33] but the link between functional platelet studies
and neurological defects is novel. A platelet and a neuron
contain both mitochondria and dense core vesicles in which
transmitters (such as serotonin) are stored. Platelets release
serotonin upon activation (Fig. 2c) and the neuronal
membrane is facilitated by a calcium dependent excita-
tion-excretion coupling mechanism. In addition, both
platelets and neurons contain functional neurotransmitter
and neuromodulator receptor sites on their outer membrane
such as adrenoceptors, serotonin receptors and serotonin
transporters. More recently it was shown that platelets also
express GABA and glutamate receptors [24, 34]. Serotonin
uptake and release by platelets and serotonin plasma levels
have been quantified and found to be altered in patients
with bipolar disorder, schizophrenia, depression, aggres-
sion, autism, migraine, etc. [19, 23, 28]. Many epidemio-
logical studies try to link these changes in activity of the
serotonin transporter or changes in the density and
responsiveness of the serotonin 2A receptor and the alpha2
adrenoceptor on the platelet membrane of these patients
with genetic polymorphism in the corresponding genes. As
for other epidemiological studies solid evidence for any
linkage is not obvious but it is irrefutable that platelet
studies have been invaluable in enabling an insight to be
gained into the role of serotonin in a number of psychiatric
and neurological disease [39, 41]. Major advances are
expected of platelet research for this field in the near future
since it is now obvious that besides the serotonin pathway,
which was only the tip of the iceberg, many other pathways
are chaired between platelets and neurons as well as the
many gene products responsible for the regulation of
granule formation, transport, secretion and endocytosis.
Conclusions
Platelet research is an expanding field originally studying
isolated thrombopathies caused by the imbalance between
thrombosis and hemostasis but more recently being able to
bring novel insights in our understanding of human
pathology in other clinical disciplines such as neurology,
endocrinology and metabolic diseases. Platelets are easily
accessible cells, and different techniques are possible to
study platelet function and morphology under basal and
activated conditions. Defects in platelet adhesion, G protein
signalling and secretion can result from mutations in
platelet-specific genes leading to isolated thrombopathies
or from mutations in widely expressed genes leading to
broader clinical phenotype including a platelet defect. In
addition to using platelet research for diagnostic purposes,
these platelet functional and morphological studies can also
be used for research aims. From the close collaboration
between clinicians of different disciplines, geneticists and
the functional platelet research unit, novel insights in the
pathogenesis of different human disorders are to be
expected in the near future by using this strategy.
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